Global Schizoaffective Disorder Size 2025, Forecast To 2034
26 Mar, 2025
What Is The Current and Historic Market Size Analysis Of The Schizoaffective Disorder Market?
The schizoaffective disorder market has seen considerable growth due to a variety of factors.
• In recent times, the schizoaffective disorder market has witnessed considerable growth. The market is projected to increase from $7.36 billion in 2024 to $7.77 billion in 2025, with a compound annual growth rate (CAGR) of 5.5%.
The augmentation during the historic period is attributable to enhanced awareness about mental health disorders, modified diagnostic criteria, increment in healthcare funding, wider access to mental health services, heightened prevalence of mental health conditions, and an increase in treatment for psychiatric illnesses.
What are the Market Size and Expected Growth Rates for the Schizoaffective Disorder Market?
The schizoaffective disorder market is expected to maintain its strong growth trajectory in upcoming years.
• The market for schizoaffective disorder is anticipated to witness robust growth in the coming years, reaching $9.47 billion in 2029 with a compound annual growth rate (CAGR) of 5.1%.
This expected growth within the forecast period can be credited to increased occurrence of mental health disorders, amplified investment in creating psychiatric medicines, heightened public consciousness about mental health disorders, growth in healthcare facilities in upcoming markets, and rise in adopting personalized medicine methods. Key trends predicted during the forecast period encompass the development of unconventional antipsychotics, embracing personalized medicine techniques, progression in digital health technology frameworks, invention in long-acting injectable treatments, superior diagnostic apparatus, incorporation of artificial intelligence in managing therapy, and better psychotherapeutic approaches.
Which Key Drivers Are Propelling The Schizoaffective Disorder Market's Growth?
The anticipated increase in neurological conditions is believed to propel the schizoaffective disorder market's expansion. Neurological conditions are health issues that impact the nervous system, including the brain, spinal cord, and nerves, resulting in a range of cognitive, motor, and sensory malfunctions. The emergence of neurological conditions can be linked to elements like genetic mutations, infections, traumatic injuries, environmental toxins, autoimmune reactions, or degenerative activities that impair the nervous system. The high frequency of neurological conditions boosts the detection and incidence of schizoaffective disorder due to shared biological mechanisms, enhanced diagnostic facilities, and increasing awareness. For example, the National Library of Medicine, a medical library in the US for medical research information, revealed in April 2023 that approximately 6.7 million Americans suffered from Alzheimer's in 2023, a figure projected to escalate to 13.8 million by 2060. Hence, the upsurge in neurological disorders is fueling the schizoaffective disorder market.
What Are The Key Segments Within The Global Schizoaffective Disorder Market?
The schizoaffective disorder market covered in this report is segmented –
1) By Drugs: Antipsychotic Medication, Mood Stabilizers, Antidepressant Medication, Anticonvulsants
2) By Causes: Genetic Factors, Environmental Factors, Chemical Factors
3) By End User: Hospitals, Clinics, Other End User
Subsegments:
1) By Antipsychotic Medication: Atypical Antipsychotics, Typical Antipsychotics
2) By Mood Stabilizers: Lithium, Valproate, Lamotrigine, Carbamazepine
3) By Antidepressant Medication: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs)
4) By Anticonvulsants: Lamotrigine, Valproate, Topiramate, Levetiracetam
What Trends Are Reshaping The Future Of The Schizoaffective Disorder Market?
Significant pharmaceutical businesses in the schizoaffective disorder market are concentrating on generating groundbreaking medications, such as extended-release injectable suspension drugs, to augment treatment effectiveness, increase patient compliance, and diminish dosing intervals. The latter is a specific form of injectable medicine meant to gradually discharge its primary component over an elongated timeline. This type of drug formulation necessitates less frequent doses compared to conventional immediate-release versions, thereby augmenting patient convenience and treatment adherence. To illustrate, in July 2024, Luye Pharma Group Ltd., a pharmaceutical enterprise based in China, made it known that the US Food and Drug Administration (FDA) had authorized ERZOFRI (paliperidone palmitate) extended-release injectable suspension for treating schizophrenia and schizoaffective disorder. This avant-garde therapy supplies a long-lasting injectable solution intended to maintain therapeutic effects over a protracted duration, thereby reducing injection frequency for patients. This extended-release approach guarantees stable medicine levels in the body, boosting patient compliance and minimising the chances of a relapse. The benefit of needing fewer injections compared to oral drugs can substantially improve the living standard for those dealing with persistent mental health disorders.
Who Are the Key Players In The Schizoaffective Disorder Market?
Major companies operating in the schizoaffective disorder market are:
• Pfizer Inc.
• Johnson & Johnson
• Bristol Myers Squibb Company
• AstraZeneca PLC
• Abbott Laboratories
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Zydus Lifesciences Limited
• Neurocrine Biosciences Inc.
• Alkermes Inc.
• Luye Pharma Group Ltd.
• Merz Pharma GmbH & Co. KGaA
• Acadia Pharmaceuticals Inc.
• Intra-Cellular Therapies Inc.
• Cerevel Therapeutics Inc.
• Avanir Pharmaceuticals Inc.
• Otsuka Pharmaceutical Co. Ltd.
• Reviva Pharmaceuticals Inc.
• Zogenix Inc.
• Sunovion Pharmaceuticals Inc.
• Newron Pharmaceuticals S.p.A.
• Sage Therapeutics Inc.
• Lyndra Therapeutics Inc.
• BioXcel Therapeutics Inc.
What Are The Regional Insights Into The Schizoaffective Disorder Market?
North America was the largest region in the schizoaffective disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the schizoaffective disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.